How is failure-free survival impacted by belumosudil in cGvHD which has failed prior therapy?

During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Aleksandr Lazaryan, MD MPH PhD, Moffitt Cancer Center, Tampa, US. We asked, How is survival impacted by belumosudil in chronic GvHD (cGvHD) which has failed prior therapy?
In this video, Lazaryan comments on belumosudil, a Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor. He also discusses the phase IIa study KD025-208 (NCT02841995), and the ROCKstar trial (NCT03640481).